174022-42-5

174022-42-5 structure

Name: Bevirimat
Chemical Name: bevirimat
CAS Number: 174022-42-5
Molecular Formula: C₃₆H₅₆O₆
Molecular Weight: 584.826
Catalog: Signaling Pathways Anti-infection HIV
Create Date: 2018-07-20 12:50:56
Modify Date: 2024-01-02 12:54:02
Bevirimat(YK FH312; FH11327; MPC-4326) is an anti-HIV drug derived from a betulinic acid-like compound; is believed to inhibit HIV by a novel mechanism, so-called maturation inhibition.IC50 value:Target: Anti-HIVLike protease inhibitors, bevirimat and other maturation inhibitors interfere with protease processing of newly translated HIV polyprotein precursor, called gag. Bevirimat prevents this viral replication by specifically inhibiting cleavage of the capsid protein (CA) from the SP1 spacer protein.

Name	bevirimat
Synonyms	DSB UNII-S125DW66N8 3-O-(3',3'-dimethylsuccinyl)betulinic acid YK FH312 YK-FH312 PA-457 BVM (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-(3-carboxy-3-methylbutanoyl)oxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid Bevirimat Butanedioic acid, 2,2-dimethyl-, 4-[(3β)-28-hydroxy-28-oxolup-20(29)-en-3-yl] ester (3β)-3-[(3-Carboxy-3-methylbutanoyl)oxy]lup-20(29)-en-28-oic acid

Description	Bevirimat(YK FH312; FH11327; MPC-4326) is an anti-HIV drug derived from a betulinic acid-like compound; is believed to inhibit HIV by a novel mechanism, so-called maturation inhibition.IC50 value:Target: Anti-HIVLike protease inhibitors, bevirimat and other maturation inhibitors interfere with protease processing of newly translated HIV polyprotein precursor, called gag. Bevirimat prevents this viral replication by specifically inhibiting cleavage of the capsid protein (CA) from the SP1 spacer protein.
Related Catalog	Signaling Pathways >> Anti-infection >> HIV Research Areas >> Infection Natural Products >> Terpenoids and Glycosides
References	[1]. Smith PF, et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother. 2007 Oct;51(10):3574-81. [2]. Salzwedel K, et al. Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Rev. 2007 Jul-Sep;9(3):162-72. [3]. Martin DE, et al. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13.

911140-87-9

~69%

174022-42-5

Literature: Krasutsky, Pavel A.; Munshi, Kalyan Patent: US2009/131714 A1, 2009 ; Location in patent: Page/Page column 8 ;

472-15-1

~72%

174022-42-5

Literature: Biotech Research Labs, Inc.; University of North Carolina at Chapel Hill Patent: US5679828 A1, 1997 ;

1189176-34-8

472-15-1

~71%

174022-42-5

Literature: REGENTS OF THE UNIVERSITY OF MINNESOTA Patent: WO2006/105356 A2, 2006 ; Location in patent: Page/Page column 27-28 ;

17347-61-4

472-15-1

~5%

174022-42-5

473-98-3

174022-42-5

4481-62-3

174022-42-5